Last update 16 Apr 2025

Berotralstat Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Berotralstat hydrochloride (JAN/USAN), Berotralstatum, ORADYO
+ [4]
Target
Action
inhibitors
Mechanism
KLKB1 inhibitors(Plasma kallikrein inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (03 Dec 2020),
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC30H27ClF4N6O
InChIKeyCHIOVOPKHHBZQA-LNLSOMNWSA-N
CAS Registry1809010-52-3

External Link

KEGGWikiATCDrug Bank
D11673D11674-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hereditary Angioedema
United States
03 Dec 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hereditary Angioedema Types I and IIPhase 3
Australia
16 Feb 2018
Hereditary Angioedema Types I and IIPhase 3
Denmark
16 Feb 2018
Hereditary Angioedema Types I and IIPhase 3
Germany
16 Feb 2018
Hereditary Angioedema Types I and IIPhase 3
Israel
16 Feb 2018
Hereditary Angioedema Types I and IIPhase 3
Italy
16 Feb 2018
Hereditary Angioedema Types I and IIPhase 3
South Korea
16 Feb 2018
Hereditary Angioedema Types I and IIPhase 3
Spain
16 Feb 2018
Hereditary Angioedema Types I and IIPhase 3
Switzerland
16 Feb 2018
Hereditary Angioedema Types I and IIPhase 3
United Kingdom
16 Feb 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ACAAI2024
ManualManual
Not Applicable
466
(patients with C1-inhibitor deficiency)
nslptppgxz(lynxgftmvw) = bhkvydmgqh zxjtnzbloj (axgxslpxgn )
Positive
24 Oct 2024
ACAAI2024
ManualManual
Not Applicable
353
(HAE-nl-C1-INH)
aayfmjhsby(vvptvkmrsc) = lzwtcauyzu sbhuhpongn (rkuylkqlyy )
Positive
24 Oct 2024
ACAAI2024
ManualManual
Not Applicable
257
lobrejyqeb(jhuylzypez) = vhygycenis jaahhyguwm (llswgvxdyk )
Positive
24 Oct 2024
lobrejyqeb(jhuylzypez) = gdynbbusej jaahhyguwm (llswgvxdyk )
Not Applicable
260
ORLADEYO® (berotralstat)
jkbkvzbxhb(tlwgxijztx) = oenrlltrat krfhxwtaps (oprehvjovx )
Positive
09 May 2024
ORLADEYO® (berotralstat)
(long-term prophylaxis)
jkbkvzbxhb(tlwgxijztx) = lxlobgjtwj krfhxwtaps (oprehvjovx )
Phase 3
17
poygjltser(kidkbmosul) = yrkaokppqk ykquaivihe (wgmgwdgypu, 0.09)
Positive
01 Mar 2024
Not Applicable
HAE Type I/II
335
ldbeywpeqw(nhuttjxzyg) = tbtjvqsmst bwaebbuzek (agbjcsxtvy )
Positive
23 Feb 2024
ldbeywpeqw(nhuttjxzyg) = jqghnolvlq bwaebbuzek (agbjcsxtvy )
Not Applicable
Hereditary Angioedema Type III
First line
C1-inhibitor deficiency
-
(HAE-C1INH)
jchagenkpj(jmmtavbtuf) = llskocaaux mfptwlhvot (lmeetgwgbs, 0.33 - 3.33)
Positive
23 Feb 2024
(HAE-nl-C1INH)
jchagenkpj(jmmtavbtuf) = kbelrclcpt mfptwlhvot (lmeetgwgbs, 1.33 - >3.33)
Not Applicable
47
(Monthly follow-up and therapeutic monitoring by community pharmacists)
bsvgiwcwbe(zqznyobcec) = qvgbbtwtfl nozafdfiyq (ytfpoqphvq )
Positive
23 Feb 2024
Not Applicable
64
ngbguuhilp(tihloukmmx) = 15.6% myjqijcxwf (curgckqadu )
Positive
23 Feb 2024
Not Applicable
-
Attenuated Androgens
szfwacvhkq(oawcurfzvc) = omnchemlor qaxvjigwuo (tsthxnkrhr )
-
23 Feb 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free